介绍详情
TAVOELITE
- Categories:Our Science
- Time of issue:2022-03-04 11:38:55
- Views:0
Current medical therapy is not without problems. Commonly used small molecule and antibody drugs both have multiple limitations.
There are several limitations of small molecule drugs:
• Small surface area exposure can limit binding affinity and specificity
• Poor modulation of protein-protein Interactions; Most designs cannot incorporate avidity or allosteric modulation
• Need for optimizing ADME
Meanwhile, there are also multiple limitations of antibody biologics as well:
• Biophysical properties prevent cell penetration and limit tissue penetration
• Many uncertainties in the drug product CMC and immunogenicity
• Manufacturing process complexity and high cost
To respond to this unmet medical need, Tavotek has created TavoELITE, a novel platform that goes after intracellular targets for the treatment of cancer and other diseases.
Features
• Enhanced target cell-specific internalization
• Efficient endosomal escape for intracellular target
• Intracellular target intervention by protein-protein interaction (modulation, inhibition or degradation) and/or through RNA modulation (silencing or delivering)
Building Blocks
• Novel molecular constructs that enhance target cell-specific internalization (e.g., VHO and VHO-Fc)
• CPP, EDD, circular RNA, etc. that enable efficient endosomal escape
• Utilizing enhanced Fc function or by conjugating small molecule engager to enable ubiquitin protease-mediated degradation
• Fab, scFv, peptide, or small molecule that specifically interact with the intracellular protein target
• Shuttled gene therapy components
© 2022 Tavotek medical All rights reserved. 苏ICP备13000009号-1
© 2021 Tavotek medical. All rights reserved. 苏ICP备20001100号-1